Skip to main content
Top
Published in: Endocrine 1/2012

01-08-2012 | Editorial

COPD and osteoporosis: something more than a comorbidity

Author: Claudio Tantucci

Published in: Endocrine | Issue 1/2012

Login to get access

Excerpt

Chronic obstructive lung disease (COPD) is a progressive functional disorder of the respiratory system with high prevalence in the older population and is presently the fourth cause of mortality and supposed to be the third in the 2020 in the world [1]. Large part of COPD morbidity and mortality is due to extra-pulmonary effects rather than pulmonary consequences of this disorder, mainly when the airway obstruction is mild or moderate [2]. Among the extra-pulmonary effects, osteopenia and osteoporosis, as a consequence of a loss of bone mineral density (BMD), have been widely recognized as a major comorbidity in COPD patients [3]. …
Literature
1.
go back to reference K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. Weel, J. Zelinski, Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532–555 (2007)PubMedCrossRef K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. Weel, J. Zelinski, Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532–555 (2007)PubMedCrossRef
2.
go back to reference P.M.A. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C.R. Jenkins, P.W. Jones, J.C. Yates, J. Vestbo, Efficacy of salmeterol and fluticasone propionate on mortality in chronic obstructive lung disease. N. Engl. J. Med. 356, 775–789 (2007)PubMedCrossRef P.M.A. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C.R. Jenkins, P.W. Jones, J.C. Yates, J. Vestbo, Efficacy of salmeterol and fluticasone propionate on mortality in chronic obstructive lung disease. N. Engl. J. Med. 356, 775–789 (2007)PubMedCrossRef
3.
go back to reference G.T. Ferguson, P.M.A. Calverely, J.A. Anderson, C.R. Jenkins, P.W. Jones, R.L. Willits, J.C. Yates, J. Vestbo, B. Celli, Prevalence and progression of osteoporosis in patients with COPD. Chest 136, 1456–1465 (2009)PubMedCrossRef G.T. Ferguson, P.M.A. Calverely, J.A. Anderson, C.R. Jenkins, P.W. Jones, R.L. Willits, J.C. Yates, J. Vestbo, B. Celli, Prevalence and progression of osteoporosis in patients with COPD. Chest 136, 1456–1465 (2009)PubMedCrossRef
4.
go back to reference A. Jebouck, S. Boonen, M. Decramer, W. Janssens, COPD, bone metabolism and osteoporosis. Chest 139, 648–657 (2011)CrossRef A. Jebouck, S. Boonen, M. Decramer, W. Janssens, COPD, bone metabolism and osteoporosis. Chest 139, 648–657 (2011)CrossRef
5.
go back to reference B. Lind, Y. Feng, The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine (2012). doi:10.1007s12020-011-9583 B. Lind, Y. Feng, The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine (2012). doi:10.​1007s12020-011-9583
6.
go back to reference H. Watz, B. Waschki, A. Kristen, K.-C. Muller, G. Kretschmar, T. Meyer, O. Holz, H. Magnussen, The metabolic syndrome in patients with chronic bronchitis and COPD. Chest 136, 1039–1104 (2009)PubMedCrossRef H. Watz, B. Waschki, A. Kristen, K.-C. Muller, G. Kretschmar, T. Meyer, O. Holz, H. Magnussen, The metabolic syndrome in patients with chronic bronchitis and COPD. Chest 136, 1039–1104 (2009)PubMedCrossRef
7.
go back to reference T.C. Mineo, V. Ambrogi, D. Mineo, A. Fabbri, E. Fabbrini, R. Massoud, Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 127, 1960–1966 (2005)PubMedCrossRef T.C. Mineo, V. Ambrogi, D. Mineo, A. Fabbri, E. Fabbrini, R. Massoud, Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 127, 1960–1966 (2005)PubMedCrossRef
8.
go back to reference S.R. Majumdar, C. Villa-Roel, K.J. Lyons, B.H. Rowe, Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Resp. Med. 104, 260–266 (2010)CrossRef S.R. Majumdar, C. Villa-Roel, K.J. Lyons, B.H. Rowe, Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Resp. Med. 104, 260–266 (2010)CrossRef
9.
go back to reference R.A. Harrison, K. Siminoski, D.B. Vethanayagam, S.R. Majumdar, Osteoporosis related kyphosis and impairments in pulmonary function: a systematic review. J. Bone Miner. Res. 22, 247–257 (2007) R.A. Harrison, K. Siminoski, D.B. Vethanayagam, S.R. Majumdar, Osteoporosis related kyphosis and impairments in pulmonary function: a systematic review. J. Bone Miner. Res. 22, 247–257 (2007)
10.
go back to reference G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef
Metadata
Title
COPD and osteoporosis: something more than a comorbidity
Author
Claudio Tantucci
Publication date
01-08-2012
Publisher
Springer US
Published in
Endocrine / Issue 1/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9686-z

Other articles of this Issue 1/2012

Endocrine 1/2012 Go to the issue